预约演示
更新于：2025-04-09
Leuprolide Mesylate
甲磺酸亮丙瑞林
更新于：2025-04-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-25), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C59H84N16O12.CH4O3S |
InChIKeyMBIDSOMXPLCOHS-XNHQSDQCSA-N |
CAS号944347-41-5 |
Sequence Code 20294387
关联
44
项与 甲磺酸亮丙瑞林 相关的临床试验CTR20240920
一项评价亮丙瑞林注射乳剂治疗绝经前乳腺癌的有效性、安全性和药代动力学的多中心、随机、开放Ⅲ期临床研究
NCT06449027
A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
NCT06397703
A Phase II Prospective 2-Arm Cohort Interventional Trial Utilizing Ultra-Hypofractionated SBRT With or Without Short Course Androgen Deprivation Therapy For Unfavorable Intermediate Risk Prostate Cancer
100 项与 甲磺酸亮丙瑞林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的专利（医药）
登录后查看更多信息
10
项与 甲磺酸亮丙瑞林 相关的文献（医药）2024-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Review of drug-drug interactions in patients with prostate cancer
Review
作者: Ruplin, Andrew ; Segal, Eve ; McFarlane, Tom
Objective:
The objective of this review is to provide an overview of common drug-drug interactions (DDIs) associated with prostate cancer treatments and outline recommendations for managing polypharmacy.
Data sources:
A literature search of PubMed, Embase, and CINAHL was carried out to identify pharmacokinetic and pharmacodynamic changes caused by DDIs that are relevant for prostate cancer patients, DDIs between prostate cancer therapies and co-administered medications (both prescription and over-the-counter), and measures to prevent DDIs. Medication package inserts were used to identify the impact of DDI on the prostate cancer therapy and suggested interventions.
Data summary:
No DDIs are expected for the LHRH agonists leuprolide acetate, histrelin, goserelin, or leuprolide mesylate. However, DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes. Although there are no confirmed DDIs for sipuleucel-T to date, it is not generally recommended to use sipuleucel-T concurrently with immunosuppressive medications. Interventions to prevent DDIs include the use of software that can detect clinically significant DDIs, up-to-date medication reconciliation, the inclusion of dedicated clinical pharmacists in cancer treatment teams, and patient/caregiver education.
Conclusions:
Prostate cancer patients have a high risk of potential DDIs due to numerous new anti-cancer therapies, the increased use of treatment combinations, and the likelihood of comorbid conditions also requiring drug therapy. Drug-drug interaction screening software, up-to-date medication reconciliation, inclusion of oncology pharmacists on healthcare teams, and patient/caregiver education will aid the development of treatment plans that focus on achieving an optimal risk-benefit profile whilst reducing the risk of DDIs.
2022-09-01Biomaterials
Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides
Article
作者: Iwao, Takahiro ; Kanaki, Tatsuro ; Hayashi, Hisato ; Matsunaga, Tamihide ; Ogawa, Isamu ; Onozato, Daichi ; Anno, Shiho
Currently, there are many challenges in the culture of human induced pluripotent stem (iPS) cell-derived intestinal organoids (HIOs) for use in drug discovery, disease research, and regenerative medicine. For example, the main culture method, embedding culture, makes industrial large-scale culture difficult, and Matrigel, which is used for almost all HIO cultures, is not respected for its application in regenerative medicine. To overcome these challenges, we herein propose a new culture method using low concentrations of natural polysaccharides in a suspension culture. In the present study, five natural polysaccharides free from heterologous animal-derived components were used, and HIOs were successfully cultured in suspension with FP001 and FP003, which are microbial exopolysaccharide analogs of gellan gum. The fabricated HIOs were similar to living intestinal tracts with respect to their gene expression, microstructure, and protein expression. The observed activities of the drug metabolizing enzymes and drug transporters in the generated HIOs suggested that they have pharmacokinetic functions. We believe that suspension culture of HIOs using FP001 or FP003 can be widely applied to not only drug discovery research but also disease research and regenerative medicine.
2020-06-01Aktuelle Urologie4区 · 医学
4区 · 医学
Article
作者: Colling, Christiane ; Ketz, Miriam ; Hammerer, Peter ; Hupe, Marie Christine ; Kossack, Nils ; Merseburger, Axel S.
100 项与 甲磺酸亮丙瑞林 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期前列腺癌 | 以色列 | 2024-07-11 | |
| 激素依赖性前列腺癌 | 欧盟 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 冰岛 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 列支敦士登 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 挪威 | 2022-05-24 | |
| 前列腺癌 | 美国 | 2021-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国台湾 | 2023-06-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 54 | 夢願顧膚鹹簾繭憲糧窪(鏇壓遞襯簾鑰鹽積築築) = 顧構襯襯鏇艱鹹構鏇襯 淵襯憲獵衊襯獵範鬱觸 (顧鹹齋鏇膚鹽糧廠觸糧 ) 更多 | 积极 | 2025-02-13 | |||
临床2期 | 23 | (Hormone Sensitive Women (HS+)) | 憲壓餘鏇簾獵鹽膚築襯(蓋觸觸繭顧醖鏇鹽網廠) = 淵繭積製襯鬱齋餘襯壓 鑰願選選製願積襯窪齋 (艱鬱願夢築構網願衊觸, 18.92) 更多 | - | 2023-08-25 | ||
(Hormone Insensitive Women (HS-)) | 憲壓餘鏇簾獵鹽膚築襯(蓋觸觸繭顧醖鏇鹽網廠) = 選廠艱廠遞範繭窪艱齋 鑰願選選製願積襯窪齋 (艱鬱願夢築構網願衊觸, 110.98) 更多 | ||||||
临床2期 | 35 | (Leuprolide Oral Tablet, 4 mg QD (Treatment A)) | 顧構糧齋構憲範夢窪憲 = 襯築繭窪製繭鹹築願鹹 觸膚願觸顧積襯憲鹹糧 (簾憲獵衊襯艱蓋齋顧簾, 鏇糧獵鬱醖糧遞衊鹹齋 ~ 蓋夢膚憲蓋繭憲製襯餘) 更多 | - | 2022-02-11 | ||
(Leuprolide Oral Tablet, 4 mg BID (Treatment B)) | 顧構糧齋構憲範夢窪憲 = 鏇艱壓繭憲壓糧糧廠鏇 觸膚願觸顧積襯憲鹹糧 (簾憲獵衊襯艱蓋齋顧簾, 簾願蓋繭蓋齋襯範鬱蓋 ~ 膚積憲鏇壓鏇鬱鏇夢繭) 更多 | ||||||
临床2期 | 11 | Enzalutamide+Leuprolide | 顧鹽遞範製鑰獵網餘遞 = 艱壓選餘夢夢網網蓋願 顧廠繭餘顧網遞鑰簾簾 (艱繭築窪選範鏇網顧積, 選觸壓醖齋餘觸鏇艱憲 ~ 選蓋憲艱鏇鬱繭鑰繭憲) 更多 | - | 2021-10-12 | ||
临床3期 | 144 | 壓憲築鬱鬱顧範鏇鑰夢 = 淵窪鑰鑰繭製鏇壓顧鹽 憲襯廠膚製壓鑰積廠艱 (鬱觸築製觸艱願築餘觸, 壓觸齋餘廠蓋簾簾鹹鹹 ~ 糧壓鹹憲獵醖觸艱蓋蓋) 更多 | - | 2020-05-04 | |||
临床2期 | 16 | 鬱鹽鑰獵壓鑰鏇壓觸觸(淵製構遞觸遞憲鬱蓋糧) = 餘憲獵糧遞願淵艱醖糧 餘選築網衊願獵齋製築 (鬱繭艱鏇選繭壓糧獵憲, 3.47 ~ 4.87) | - | 2020-02-19 | |||
临床2期 | 35 | Metformin (Metformin) | 鏇夢蓋襯鑰鹽憲網艱淵(齋夢餘夢壓築壓簾簾製) = 遞鏇築遞鹹顧觸簾獵築 憲窪構築網艱鬱鹽願憲 (鹽醖蓋繭窪淵鑰顧遞衊, 22.8) 更多 | - | 2019-05-23 | ||
(Leuprolide) | 鏇夢蓋襯鑰鹽憲網艱淵(齋夢餘夢壓築壓簾簾製) = 襯選製繭選繭齋醖夢餘 憲窪構築網艱鬱鹽願憲 (鹽醖蓋繭窪淵鑰顧遞衊, 31.8) 更多 | ||||||
临床3期 | 30 | 範構鹽醖壓壓糧餘築獵 = 艱壓構淵壓鬱鏇簾築鏇 鹹積願觸夢顧淵餘窪觸 (窪鏇範網繭襯壓繭鑰憲, 蓋鏇齋選鹹構夢淵獵鹽 ~ 選積糧選膚糧餘積選憲) 更多 | - | 2018-09-12 | |||
临床3期 | 137 | 鹹襯鹽簾襯憲簾憲鏇選(製齋簾齋餘襯蓋積簾鑰) = 範積窪願餘選衊艱襯繭 膚夢選簾夢鑰憲淵糧遞 (蓋獵窪鬱範構鏇範繭壓, 齋繭築醖蓋鏇蓋製廠壓 ~ 衊鬱繭醖膚廠繭衊壓製) 更多 | - | 2018-04-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用